Literature DB >> 35927341

Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.

Wei Han1, Juan Wu1, Peipei Zhang1, Naizhong Hu1, Qiao Mei1, Jing Hu2.   

Abstract

PURPOSE: Fecal calprotectin (FC) levels can reflect the level of intestinal inflammation. Crohn's disease (CD), which affects the small bowel, has not been linked to FC levels. We determined if FC levels and endoscopic activity were related by performing double-balloon endoscopy (DBE).
METHODS: Herein, patients with small bowel CD diagnosed by DBE between January 2020 and January 2022 were prospectively observed. Feces and blood samples of patients were collected before performing DBE and checked for the levels of FC and serological biomarkers. The endoscopic activity and mucosal healing (MH) were evaluated using the partial simple endoscopic score (pSES-CD).
RESULTS: In all 254 CD patients, FC levels were correlated with pSES-CD (r = 0.775, P < 0.001). Even in patients with isolated small bowel CD, FC levels were strongly correlated with pSES-CD (r = 0.753, P < 0.001). In all patients, FC as an endoscopic remission indicator was found to have an area under the curve (AUC) of 0.872, with a cut-off value of 156.09 µg/g. In patients with isolated small bowel CD, FC yielded a high AUC of 0.865 for predicting endoscopic remission, with a cut-off value of 211.48 µg/g, sensitivity of 73.95%, and specificity of 91.30%. FC was optimally cut-off at 76.99 µg/g to predict MH in accordance with the AUC of 0.877.
CONCLUSIONS: Using DBE findings, FC was found to be significantly correlated with pSES-CD. Even in isolated small bowel CD, FC may be a more reliable marker of accurately predicting endoscopic remission and MH.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Crohn’s disease; Double-balloon endoscopy; Endoscopic remission; Fecal calprotectin; Mucosal healing

Mesh:

Substances:

Year:  2022        PMID: 35927341     DOI: 10.1007/s00384-022-04232-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  25 in total

1.  Double-balloon enteroscopy in Crohn's disease: findings and impact on management in a multicenter retrospective study.

Authors:  Adam Rahman; Andrew Ross; J A Leighton; Drew Schembre; Lauren Gerson; Simon K Lo; Irving Waxman; Charles Dye; Carol Semrad
Journal:  Gastrointest Endosc       Date:  2015-04-01       Impact factor: 9.427

2.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

3.  Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn's disease of the small bowel.

Authors:  Christian Schulz; Klaus Mönkemüller; Maxi Salheiser; Michael Bellutti; Kerstin Schütte; Peter Malfertheiner
Journal:  Dig Endosc       Date:  2013-07-16       Impact factor: 7.559

4.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.

Authors:  E Louis; A Collard; A F Oger; E Degroote; F A Aboul Nasr El Yafi; J Belaiche
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

5.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

Authors:  Marco Daperno; Geert D'Haens; Gert Van Assche; Filip Baert; Philippe Bulois; Vincent Maunoury; Raffaello Sostegni; Rodolfo Rocca; Angelo Pera; Annemie Gevers; Jean-Yves Mary; Jean-Frédéric Colombel; Paul Rutgeerts
Journal:  Gastrointest Endosc       Date:  2004-10       Impact factor: 9.427

6.  Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.

Authors:  Paul J Limburg; Mary E Devens; Jonathan J Harrington; Nancy N Diehl; Douglas W Mahoney; David A Ahlquist
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

7.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

Review 8.  Small bowel Crohn's disease: an emerging disease phenotype?

Authors:  Barry Hall; Grainne Holleran; Deirdre McNamara
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

9.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

Authors:  Kathrine Frey Frøslie; Jørgen Jahnsen; Bjørn A Moum; Morten H Vatn
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

10.  Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review.

Authors:  Ebby George Simon; Richard Wardle; Aye Aye Thi; Jeanette Eldridge; Sunil Samuel; Gordon William Moran
Journal:  Intest Res       Date:  2019-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.